Trial Profile

A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Puxitatug samrotecan (Primary) ; Rilvegostomig (Primary)
Indications Advanced breast cancer; Biliary cancer; Carcinoma; Cholangiocarcinoma; Endometrial cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms BLUESTAR
Sponsors AstraZeneca; AstraZeneca AB

02 Mar 2026 According to Compugen Ltd media release, further clinical data anticipated from this trail is expected in this year.
08 Dec 2025 Planned number of patients changed from 370 to 460.
09 Oct 2025 Planned End Date changed from 26 Mar 2027 to 29 Sep 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com